Wednesday, July 10, 2024

 

Federal regulator: Pharmacy middlemen appear to be ...

2 hours ago — For its part, and industry group representing PBMs said the businesses “have a proven track record of reducing prescription drug costs” and that they “recognize ...

 

Advertising and labelling compounded preparations must ...

1 day ago — As indicated in the Food and Drug Regulations, if prescription drugs (including compounded preparations) are advertised, the advertisement can only indicate ...

 

North Carolina Board of Pharmacy

5 days ago — McLaughlin is from New Bern, NC, and is the president and chief executive officer of Realo Drugs ... compounded such drug.” Board staff have received calls from 

 

24.36.01 – rules of the idaho state board of pharmacy

5 days ago — The sterility of compounded diagnostics, drugs, nutrients, and radiopharmaceuticals must be maintained or the compounded drug preparation must be

 

7 days ago — Day's presentation focused on regulatory confusion surrounding permissible compounding of ketamine, as well as best practices for compounding as recently ...

 

'Compounded' weight-loss drugs are a growing problem for ...

2 days ago — The state medical board has a rule that only medications that have been FDA-approved for weight loss can be prescribed for weight loss — meaning compounded ...

Department of Justice News: U.S. Compounding, Inc. Pleads Guilty To Multiple Fraud Offenses And Company Vice President Indicted In Scheme To Distribute Drugs, including Veterinary Drugs, Nationally Using False Prescriptions U.S. Compounding, Inc., a Subsidiary of a Publicly Traded Company, Pled Guilty to Mail Fraud and Food, Drug, and Cosmetic Act Offense

 Damian Williams, the United States Attorney for the Southern District of New York, and Christie M. Curtis, the Acting Assistant Director in Charge of the New York Field Office of the Federal Bureau of Investigation (“FBI”), announced today that U.S. COMPOUNDING, INC. (“USC”), a subsidiary of DMK Pharmaceuticals Corporation, pled guilty to multiple fraud offenses before U.S. District Judge Arun Subramanian, and a former USC executive, SAM GLOVER, was charged in an Indictment with conspiring to violate the Food, Drug, and Cosmetic Act (“FDCA”). GLOVER was arrested this morning and is expected to be presented today before a U.S. Magistrate Judge in the Eastern District of Arkansas.

FBI Acting Assistant Director in Charge Christie M. Curtis said: “U.S. Compounding, Inc. and its former executive, Sam Glover, allegedly committed various frauds and violated the Food Drug and Cosmetic Act by falsifying prescription orders. Despite scrutiny by members of the company who suspected the orders were unverified, the company’s leadership continued to allow the requests and collect profits as a result. This investigation is part of the FBI’s larger effort to ensure that both individuals and organizations who devise complex fraud schemes are prevented from furthering their illegitimate arrangements and making money off mistruths.”

Read More Button

 

Tuesday, July 2, 2024

 On Friday, the FDA's Center for Veterinary Medicine made available two webinars for stakeholders interested in FDA regulation of intentional genomic alterations in animals. The webinars focus on two guidance documents: final Guidance for Industry #187A, “Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,” and draft Guidance for Industry #187B, “Heritable Intentional Genomic Alterations in Animals: The Approval Process.” The webinars provide historical background on the guidances and walk through the details of what they cover. These and other webinars are available in the agency’s Animal Biotechnology Products Resource Center.